جستجوی استاد راهنمای دانشگاهی

• Pharmacology
• Molecular Pharmacology
• Drug Design
• +۵ مورد دیگر

Anders A. Jensen is a Professor in the Department of Drug Design and Pharmacology at the University of Copenhagen's Faculty of Health and Medical Sciences, specializing in Molecular and Cellular Pharmacology. His research focuses on receptor pharmacology, particularly calcium-sensing receptors and serotonin 5-HT2A receptors, with significant contributions to understanding receptor modulation and drug development. Professor Jensen's research interests span molecular pharmacology, drug design, and receptor signaling mechanisms. His work particularly emphasizes calcium homeostasis disorders, allosteric modulation of receptors, and the development of novel compounds targeting serotonin receptors for neurological conditions. He has made significant contributions to understanding the structure-function relationships of G protein-coupled receptors and their implications for drug discovery. Analysis of his recent publications reveals a strong focus on receptor pharmacology with particular emphasis on calcium-sensing receptors and serotonin 5-HT2A receptors. His research spans both basic molecular mechanisms and translational applications, with work ranging from nanobody development to novel therapeutic compounds for pain management and depression. The publications demonstrate expertise in receptor kinetics, structure-activity relationships, and the molecular basis of receptor-related disorders. Professor Jensen maintains active research collaborations across multiple institutions and has founded and directs Drug Design and Pharmacology at Lophora (www.lophora.com), though this is noted as a separate activity from his university employment. His research output includes 194 publications with significant impact in pharmacology and related fields.

• Structural Biology
• Pharmacology
• X-ray Crystallography
• +۵ مورد دیگر

Karla Andrea Frydenvang is an Associate Professor in the Department of Drug Design and Pharmacology at the Faculty of Health and Medical Sciences, University of Copenhagen. With a career spanning over three decades since earning her PhD in 1989, she has established herself as a leading researcher in structural pharmacology and neuropharmacology. Current Position: Associate Professor (2002-present) Previous Appointments: Assistant Professor (1989-1990), Research Fellowships (1990-2002) Education: Cand. pharm. (1985), PhD pharm. (1989) from Royal Danish School of Pharmacy Dr. Frydenvang's research focuses on membrane-bound ionotropic glutamate receptors, particularly examining the extracellular ligand-binding domain expressed from E. coli. Her work analyzes protein complexes with various ligands to understand binding affinity, selectivity, and specificity through X-ray crystallographic studies. This structural approach has yielded significant insights into receptor function and modulation. Her recent publications (2022-2024) demonstrate a strong focus on glutamate receptor pharmacology, particularly AMPA and kainate receptors, with several papers examining positive allosteric modulators. Additional research areas include AKR1C3 inhibitors for prostate cancer and serotonin receptor agonists, showing the breadth of her structural pharmacology expertise. The publications reveal a consistent pattern of structural biology approaches applied to neuropharmacology and cancer drug development. Alfred Benzon Research Fellowship (1994-1997) Bøje Benzon Research Fellowship (1999-2002) Member of the Danish National Committee for Crystallographers since 1999 As an educator, Dr. Frydenvang participates in teaching pharmacy students through lectures, seminars, and practical courses in organic chemistry and philosophy of science. She has contributed to developing specialized courses including 'Structural and Computational Medicinal Chemistry' and 'Medicines: Design, Development, Delivery and Use.' Her mentorship extends to advising master's students and serving as advisor and external examiner for PhD candidates. Her leadership roles include chairing the department's teaching committee from 2009-2012.

Jesper Langgaard Kristensenمشاهده پروفایل

استاد

• Medicinal Chemistry
• Serotonin Receptor Pharmacology
• Psychedelic Compound Development
• +۵ مورد دیگر

Jesper Langgaard Kristensen is a Professor in Medicinal Chemistry at the Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen. His research focuses on developing new methodologies for constructing compound classes relevant to medicinal chemistry and creating probes to elucidate mechanisms regulating pharmacological targets including ion channels, enzymes, and GPCRs. Education: Cand. Pharm. (1998), including 6 months research with Prof. Dieter Hoppe in Münster Ph.D. from Danish University of Pharmaceutical Sciences (2001), including 6 months research with Prof. Barry Trost at Stanford University Professor Kristensen's research spans medicinal chemistry, neuroscience, and imaging, with a particular focus on serotonin receptors, especially the 5-HT2A receptor. His work bridges chemical synthesis with pharmacological characterization to develop novel compounds with therapeutic potential, particularly in the areas of psychedelic medicine and neurodegenerative disorders. He has made significant contributions to understanding structure-activity relationships of serotonergic compounds and their potential as therapeutic agents. His publication record shows a strong trend toward developing selective serotonin receptor agonists, particularly targeting the 5-HT2A receptor for potential applications in depression treatment. Recent work also explores imaging technologies for neurological disorders, reflecting his dual expertise in medicinal chemistry and diagnostic applications. His research often involves interdisciplinary collaboration across chemistry, pharmacology, and neuroscience. Scientific Awards and Recognition: Member of Horizon2020 "Click-It" consortium (6 million Euro, 2015-2020) Member of Marie Curie ETN "AlphaSy" consortium (4.1 million Euro, 2018-2022) Coordinator of ETN-EID project SAFER (1.3 million Euro, 2017-2021) Professor Kristensen has secured significant research funding through competitive European grants and collaborates extensively with international research teams. His research group actively mentors students and researchers, contributing to the next generation of medicinal chemists. He also serves as CSO and founder of Lophora (www.lophora.com), translating academic research into commercial applications. The Kristensen Group at the University of Copenhagen operates at the intersection of chemical synthesis and pharmacological evaluation, with facilities for organic synthesis, molecular modeling, and biological testing. The group participates in several international consortia focused on developing novel therapeutic and diagnostic approaches for neurological and psychiatric conditions.

• Pharmacology
• Neuropharmacology
• Ion Channel Research
• +۴ مورد دیگر

Uffe Kristiansen is an Associate Professor in the Department of Drug Design and Pharmacology at the University of Copenhagen's Faculty of Health and Medical Sciences. His research focuses on ionotropic receptors for inhibitory amino acids, particularly GABA and glycine receptors, with emphasis on their relation to epilepsy. Dr. Kristiansen's primary research areas include: Pharmacodynamics of fast, desensitizing receptors Kinetics of ligand-receptor interaction at $$\text{GABA}_{\text{A}}$$ receptors Inhibitory neurotransmission mechanisms Receptor selectivity through kinetic principles His laboratory employs a combination of patch-clamp electrophysiology with variable rates of ligand application, different methods of response measurements, and kinetic computer modeling to optimize experimental design and quantification methods. This approach increases information yield and validity of conclusions in pharmacological studies. A notable concept developed by his team is 'receptor selectivity by kinetics,' which leverages the inherent differences in time-concentration profiles of neurotransmitters at synaptic versus extrasynaptic receptors to improve drug selectivity. Dr. Kristiansen's research publications span pharmacology, neuroscience, and computational modeling, with recent work focusing on $$\text{GABA}_{\text{A}}$$ receptor antagonists, ion channel kinetics, and novel approaches to studying inhibitory neurotransmission. His work has implications for developing more selective treatments for neurological disorders, particularly epilepsy. His scientific contributions include: Development of kinetic models for receptor interactions Studies on receptor selectivity mechanisms Investigations of $$\text{GABA}_{\text{A}}$$ receptor pharmacology Research on ion channel function in neurological disorders Dr. Kristiansen teaches courses in general physiology, neurophysiology and pharmacology, pharmacodynamics, and ion channel kinetics, contributing to the education of future pharmacologists and neuroscientists.

• Medicinal Chemistry
• Neuroscience
• GPCR Pharmacology
• +۳ مورد دیگر

Emil Märcher-Rørsted is a PhD student and Guest Researcher at the University of Copenhagen's Department of Drug Design and Pharmacology within the Faculty of Health and Medical Sciences. His academic background includes an MSc in Medicinal Chemistry (2016) focused on bitopic inhibitors for β2-adrenergic receptors, and a BSc in Pharmacy investigating EAAT inhibitors. Research interests center on: Design of serotonin receptor-targeted compounds GPCR ligand binding mechanisms Therapeutic applications of psychedelics Neuropharmacology of serotonergic systems Small molecule drug development Publication analysis reveals consistent focus on serotonin receptor agonists (particularly 5-HT 2A ), neuropharmaceutical development, and molecular pharmacology techniques. Recent work demonstrates increasing emphasis on antidepressant applications and receptor binding dynamics. Currently supervised by Jesper L. Kristensen, his laboratory focuses on psychedelic neurochemistry and receptor pharmacology.